Search clinical trials for: BI phone calls

Total 6143 results

The University of Texas Health Science Center at...

Completed

Improving Adherence to EHT Among Breast Cancer Patients

Breast Cancer

United States
University of Otago
oVRcome

Completed

oVRcome - Self Guided Virtual Reality for Social Anxiety Disorder

Social Anxiety

New Zealand
Hikma Pharmaceuticals LLC
Winterlight Labs

Completed

Using Speech to Monitor Symptom Severity in Arabic Speaking Patients With Schizophrenia

Schizophrenia

Algeria, Egypt, Jordan, Saudi Arabia
Asthma Research Group Windsor-Essex Inc
University Health Network, Toronto

Active, not recruiting

A Digital Respiratory Ecosystem for People Living With Asthma

Asthma

Canada
Cumhuriyet University

Completed

The Effect of Nursing Follow-Up by Phone on The Self-Efficacy,Pain,Disease Activity in Rheumatoid Arthritis Patients

Tele-nursing

Turkey
University of Cambridge

Completed

Clinical Application and Functionality for an Application for Measurement of Head Circumference.

Hydrocephalus in Infants

United Kingdom
Jaseng Medical Foundation

Completed

Long Term Follow-Up of Traumatic Fracture Patients Treated With Integrated Complementary and Alternative Medicine: Observational Study

Fractures, Bone | Medicine, Korean Traditional

Korea, Republic of
Sidney Kimmel Cancer Center at Thomas Jefferson...

Terminated

Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors

Breast Cancer

United States
Centre Leon Berard
Institut National de la Santé Et de la Recherche Médicale, France; National...

Completed

A Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures and the Risk of Testicular Germ Cell Tumor (TESTIS)

Testicular Germ Cell Tumor

France
Boehringer Ingelheim

Withdrawn

Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroids

Asthma
Boehringer Ingelheim

Completed

BI 894999 First in Human Dose Finding Study in Advanced Malignancies

Neoplasms | NUT Carcinoma

United States, Spain, Belgium, Germany, France, Korea, Republic of
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 1015550 Are Taken up in the Body of Healthy Japanese Men

Healthy

Japan
Boehringer Ingelheim

Completed

A Study in Healthy Chinese People to Test How Different Doses of BI 1015550 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

Pancreatic Neoplasms

Austria, Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 765080 is Taken up in the Body When Given as an Injection Under the Skin Compared With an Infusion Into the Vein

Healthy

Belgium
Boehringer Ingelheim

Completed

Dose Finding Study of BI 836880 in Patients With Solid Tumors

Neoplasms

Germany, France
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 1467335 is Processed in the Body

Healthy | Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the Body

Healthy | Chronic Kidney Disease

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Netherlands
Boehringer Ingelheim

Completed

Weekly BI 836880 in Patients With Advanced Solid Tumors

Neoplasms

Spain, France
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours

Neoplasms

Hungary
Boehringer Ingelheim

Completed

BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse

Leukemia, Myeloid, Acute

United States
Boehringer Ingelheim

Completed

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Wet Macular Degeneration

Austria, Germany, Hungary
Boehringer Ingelheim

Completed

Bioavailability of 3 Different Formulations of BI 207127 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

BI 811283 in Various Solid Tumours

Neoplasms

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects

Healthy Volunteers

Germany
Baxalta now part of Shire

Completed

Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen

Hemophilia A | Hemophilia B

Japan, Russian Federation, Spain, United States, Poland, Romania, Serbia, Taiwan, Ukraine
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)

Recruiting

Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer (ACCESS)

Metastatic Breast Cancer | Stage IV Breast Cancer AJCC V7

United States
General Health Council, Mexico
Eli Lilly and Company; Instituto de Seguridad y Servicios Sociales de los Trabajadores...

Recruiting

Development of an Information Board and Mobile Application for the Care of Type 2 Diabetes (SANENT)

Diabetes Mellitus, Type 2

Mexico
Tufts Medical Center
National Institute on Minority Health and Health Disparities (NIMHD)

Active, not recruiting

Community Walks: Clinical Trial

Physical Inactivity

United States
University of South Carolina
Centers for Disease Control and Prevention

Active, not recruiting

Phone-Based Based Walk With Ease Program for Adults With Arthritis

Arthritis | Osteoarthritis | Rheumatoid Arthritis | Lupus Erythematosus, Systemic | Fibromyalgia | Gout

United States
Canterbury Christ Church University

Terminated

Can You Reduce Problematic Smartphone Use Through a Group Intervention: A Single Case Experimental Design

Addiction, Smartphone

United Kingdom
Alexandria University
High Institute of Public Health, Egypt

Completed

Short Message Service for Type 2 Diabetes (SMS4T2D)

Diabetes Mellitus, Type 2

Egypt
Chulalongkorn University
Thai Red Cross AIDS Research Centre; International AIDS Society

Completed

Youth-focused Strategies to Promote Adherence to Pre-exposure Prophylaxis Among Youth At-risk for HIV in Thailand (YouthPrEP)

HIV Prevention | Adherence, Medication | Adolescent Behavior | Mobile Health | Sexual Health

Thailand
Maastricht University Medical Center

Completed

Effect of Individualized Patient Education Including Drinking Advice Using an App

Colorectal Cancer

Netherlands
Jordi Gol i Gurina Foundation

Completed

Effectiveness of Midwife Phone Support With the to Reduce the Early Abandonment of Breastfeeding (STAM)

Breastfeeding
Indiana University

Completed

Mobile Communication Technology for Adolescents With Diabetes

Type 1 Diabetes

United States
Adiyaman University Research Hospital

Completed

Use of WhatsApp for Communication Between Consulting Physicians and the Emergency Physicians (whatsapp)

Consultation

Turkey
Northwestern University

Completed

Text Messaging and Atopic Dermatitis

Atopic Dermatitis

United States
OSE Immunotherapeutics
Boehringer Ingelheim

Active, not recruiting

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Solid Tumor, Adult

France, Belgium
Boehringer Ingelheim

Completed

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

Neoplasms

Japan
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour

Neoplasms

Belgium
Boehringer Ingelheim

Terminated

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Healthy

Germany
Peking University

Unknown

Screening and Treatment of SAHS in Patients With Acute Ischemic Stroke (SAHS)

Ischemic Stroke | Sleep Apnea Syndrome

China
Boehringer Ingelheim

Completed

Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers

Healthy

Germany
M.D. Anderson Cancer Center
Boehringer Ingelheim

Terminated

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Breast Cancer

United States
M.D. Anderson Cancer Center
GlaxoSmithKline

Withdrawn

Phase II Study of Pazopanib and Topotecan in Cervical Cancer

Cervical Cancer
Boehringer Ingelheim

Completed

Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers

Healthy

3

Subscribe